The first class of new drug uropolypeptide injection of tailing medicine was approved for marketing
-
Last Update: 2017-01-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The national class 1.1 new drug, xitique (niacin injection), developed by thaling biopharmaceutical Jiangsu Co., Ltd., a subsidiary of thaling pharmaceutical, has been approved by the State Food and Drug Administration for listing, and the drug approval number is gyzz h20163446 Xitique (trade name of uropoietin injection), a national class 1.1 new drug, has global exclusive intellectual property rights and related patents, and has been approved by CFDA for listing, which is used to treat non-small cell lung cancer and breast cancer The new indication is myelodysplastic syndrome (MDS) MDS is a kind of malignant hematopathy, about one third of patients will develop leukemia CFDA has approved the new indications for MDS treatment to enter phase II clinical The clinical research is being carried out in 15 clinical research centers (hospitals) across the country The research has been included in the "major new drug creation" special project alternative database of the Ministry of science and technology of the people's Republic of China Siliqua will be produced and marketed by thaling biopharmaceutical The approval of the listing of the company shows that the company and its subsidiaries have made significant breakthroughs in new drug innovation This product is unique and exclusive, which will expand the product portfolio of the group's products in the field of tumor treatment and bring strong support for the group's operation.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
